Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Medical Officer | September 07, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UroGen Pharma Ltd.
Report date September 07, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 59,882 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-07 · Exercise / conversion · Acquired 1,667 · Balance 60,753 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2026-09-08 · Sale · Disposed 871 · Balance 59,882 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-07 · Exercise / conversion · Disposed 1,667 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2021 Filed Oct 28, 2021 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-061868 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209 Underlying: Ordinary Shares · 208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-061868 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 23:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 243 | $15.64 | $3,800.52 |
DisclosureSEC source: 0001209191-21-049477 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,494 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| July 31, 2021 Filed Aug 3, 2021 23:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049477 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| July 31, 2021 Filed Aug 3, 2021 23:07 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-049477 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 13:11 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048398 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Underlying: Ordinary Shares · 208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 13:11 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 103 | $15.30 | $1,575.90 |
DisclosureSEC source: 0001209191-21-048398 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,821 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 13:11 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-048398 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| April 30, 2021 Filed May 4, 2021 17:58 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029758 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Ordinary Shares · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| April 30, 2021 Filed May 4, 2021 17:58 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 243 | $20.00 | $4,860.00 |
DisclosureSEC source: 0001209191-21-029758 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,132 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| April 30, 2021 Filed May 4, 2021 17:58 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029758 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 17:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 209 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028500 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Ordinary Shares · 209 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 17:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 89 | $19.63 | $1,747.07 |
DisclosureSEC source: 0001209191-21-028500 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,875 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 17:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028500 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 19:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006699 · doc4.xml · derivative · entry 5 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024 F5 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024 Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 19:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001209191-21-006699 · doc4.xml · derivative · entry 4 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2031-01-31 F4 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024 Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 19:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006699 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 19:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,076 | $22.07 | $23,747.32 |
DisclosureSEC source: 0001209191-21-006699 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,755 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 19:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-006699 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 26, 2021 Filed Jan 26, 2021 22:20 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005460 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 Underlying: Ordinary Shares · 208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| January 26, 2021 Filed Jan 26, 2021 22:20 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 100 | $22.12 | $2,212.00 |
DisclosureSEC source: 0001209191-21-005460 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,831 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 26, 2021 Filed Jan 26, 2021 22:20 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-005460 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 20:59 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061921 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on December 7, 2017 representing 12,500 ordinary shares. 33.33% of the RSUs vested on December 4, 2018 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on December 7, 2017 representing 12,500 ordinary shares. 33.33% of the RSUs vested on December 4, 2018 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 20:59 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 662 | $19.85 | $13,140.70 |
DisclosureSEC source: 0001209191-20-061921 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,723 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 20:59 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-061921 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 18:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056066 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042 Underlying: Ordinary Shares · 208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 18:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 101 | $20.95 | $2,115.56 |
DisclosureSEC source: 0001209191-20-056066 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,343 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 18:12 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056066 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 20:48 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049741 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042 Underlying: Ordinary Shares · 1,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on December 7, 2017 representing 12,500 ordinary shares. 33.33% of the RSUs vested on December 4, 2018 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on December 7, 2017 representing 12,500 ordinary shares. 33.33% of the RSUs vested on December 4, 2018 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 20:48 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 348 | $20.20 | $7,029.60 |
DisclosureSEC source: 0001209191-20-049741 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,236 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 20:48 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-049741 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| July 27, 2020 Filed Jul 28, 2020 21:32 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 70 | $23.51 | $1,645.70 |
DisclosureSEC source: 0001209191-20-043873 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,543 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| July 26, 2020 Filed Jul 28, 2020 21:32 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 209 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043873 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Ordinary Shares · 209 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| July 26, 2020 Filed Jul 28, 2020 21:32 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043873 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 18:31 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034672 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,083 Underlying: Ordinary Shares · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on December 7, 2017 representing 12,500 ordinary shares. 33.33% of the RSUs vested on December 4, 2018 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on December 7, 2017 representing 12,500 ordinary shares. 33.33% of the RSUs vested on December 4, 2018 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 18:31 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 349 | $27.51 | $9,601.97 |
DisclosureSEC source: 0001209191-20-034672 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,404 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 18:31 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034672 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| April 27, 2020 Filed Apr 28, 2020 17:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 70 | $24.35 | $1,704.50 |
DisclosureSEC source: 0001209191-20-025904 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,711 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 17:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025904 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,459 Underlying: Ordinary Shares · 208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 17:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-025904 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 04, 2020 Filed Mar 4, 2020 22:28 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016275 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Ordinary Shares · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · kind: The transaction reported herein was matchable under Section 16(b) of the Securities and Exchange Act of 1934, to the extent of 345 shares, with the reporting person's purchase of 1,960 ordinary shares of the Issuer at a price of $28.17 per share on November 19, 2019. The reporting person has paid to the Issuer $458.85, representing the full amount of the profit realized in connection with the short-swing transaction. F4 · derivative.exercise_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of three years. F4 · derivative.expiration_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of three years. Read SEC document |
| March 04, 2020 Filed Mar 4, 2020 22:28 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Tax withholdingOrdinary Shares | 345 | $29.50 | $10,177.50 |
DisclosureSEC source: 0001209191-20-016275 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,573 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| March 04, 2020 Filed Mar 4, 2020 22:28 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016275 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 17:38 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted stock unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006210 · doc4.xml · derivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F3 · derivative.expiration_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 17:38 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock options (right to buy) · Derivative | 15,000 | $0.00 Strike: $29.41 | $0.00 |
DisclosureSEC source: 0001209191-20-006210 · doc4.xml · derivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F1 · derivative.expiration_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:10 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 322 | $29.15 | $9,386.30 |
DisclosureSEC source: 0001209191-20-005200 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,177 F2 · kind: The transaction reported herein was matchable under Section 16(b) of the Securities and Exchange Act of 1934, to the extent of 322 shares, with the reporting person's purchase of 1,960 ordinary shares of the Issuer at a price of $28.17 per share on November 19, 2019. The reporting person has paid to the Issuer $315.56, representing the full amount of the profit realized in connection with the short-swing transaction. F3 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 22:10 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005200 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Ordinary Shares · 833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 2,500 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F4 · derivative.expiration_date: The reporting person was granted 2,500 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 22:10 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-005200 · doc4.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 18:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059250 · doc4.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Underlying: Ordinary Shares · 1,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · kind: The transaction reported herein was matchable under Section 16(b) of the Securities and Exchange Act of 1934, to the extent of 343 shares, with the reporting person's purchase of 1,960 ordinary shares of the Issuer at a price of $28.17 per share on November 19, 2019. The reporting person has paid to the Issuer $1,207.36, representing the full amount of the profit realized in connection with the short-swing transaction. F4 · derivative.exercise_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of three years. F4 · derivative.expiration_date: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of three years. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 18:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Tax withholdingOrdinary Shares | 343 | $31.69 | $10,869.67 |
DisclosureSEC source: 0001209191-19-059250 · doc4.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,666 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.